Medtronic Diabetes Enhances Insulin Delivery with Medicare Access and FDA Approvals
Medtronic Diabetes Enhances Insulin Delivery Options
Medtronic, a renowned leader in healthcare technology, has recently made waves in the diabetes management sphere with three substantial achievements that aim to empower patients living with type 1 and insulin-requiring type 2 diabetes. These milestones include Medicare approval for the MiniMed™ 780G system integrated with the Instinct sensor by Abbott, FDA clearances for its utilization with ultra-rapid acting insulins, and authorization for use in insulin-requiring type 2 diabetes populations.
Expanding Access to Insulin Solutions
With Medicare and Medicare Advantage beneficiaries now able to access the MiniMed™ 780G system coupled with the Instinct sensor, users can experience enhanced options for managing their diabetes. The Instinct sensor is low-profile, discreet, and boasts a wear time of up to 15 days, representing an improvement in technology that can ease the burden of diabetes management. Patients can also leverage additional sensor options such as the Simplera Sync™ and Guardian™ 4 sensors.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.